DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Actos (Pioglitazone Hydrochloride) - Published Studies

 
 



Actos Related Published Studies

Well-designed clinical trials related to Actos (Pioglitazone)

Pioglitazone for Hepatic Steatosis in HIV/HCV Co-infection. [2015]

Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study. [2013]

Clinical efficacy of pioglitazone: generic vs. original product. [2012]

Pioglitazone-mediated changes in lipoprotein particle composition are predicted by changes in adiponectin level in type 2 diabetes. [2012]

Rosiglitazone and pioglitazone for the treatment of Alzheimer's disease. [2011.11]

Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study. [2011.11]

Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus. [2011.10]

Effect of pioglitazone on endothelial dysfunction after sirolimus-eluting stent implantation. [2011.07.15]

Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study. [2011.07.14]

Effect of pioglitazone and ramipril on biomarkers of low-grade inflammation and vascular function in nondiabetic patients with increased cardiovascular risk and an activated inflammation: results from the PIOace study. [2011.07.01]

Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. [2011.07]

Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects. [2011.07]

Leptin replacement improves postprandial glycemia and insulin sensitivity in human immunodeficiency virus-infected lipoatrophic men treated with pioglitazone: a pilot study. [2011.07]

Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. [2011.06]

Effects of metformin and pioglitazone on serum pentosidine levels in type 2 diabetes mellitus. [2011.06]

PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia. [2011.06]

DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. [2011.06]

Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes. [2011.06]

Efficacy and safety of the PPARgamma partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy. [2011.05]

Effects of pioglitazone versus metformin on circulating endothelial microparticles and progenitor cells in patients with newly diagnosed type 2 diabetes-a randomized controlled trial. [2011.05]

Pioglitazone for diabetes prevention in impaired glucose tolerance. [2011.03.24]

Role of pioglitazone in the prevention of restenosis and need for revascularization after bare-metal stent implantation: a meta-analysis. [2011.03]

Pioglitazone improves endothelial and adipose tissue dysfunction in pre-diabetic CAD subjects. [2011.03]

Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment. [2011.02]

Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study. [2011.01.11]

Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. [2011.01]

Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus. [2011.01]

Exercise training augments the peripheral insulin-sensitizing effects of pioglitazone in HIV-infected adults with insulin resistance and central adiposity. [2011.01]

A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. [2011.01]

Comparison of metabolic profile and adiponectin level with pioglitazone versus voglibose in patients with type-2 diabetes mellitus associated with metabolic syndrome. [2011]

Truncated areas under the curve in the assessment of pioglitazone bioequivalence. Data from a single-center, single-dose, randomized, open-label, 2-way cross-over bioequivalence study of two formulations of pioglitazone 45 mg tablets under fasting conditions. [2011]

Efficacy and safety of combination therapy with candesartan cilexetil and pioglitazone hydrochloride in patients with hypertension and type 2 diabetes mellitus. [2011]

Rosiglitazone and pioglitazone for the treatment of Alzheimer's disease. [2011]

Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study. [2011]

Pioglitazone for diabetes prevention in impaired glucose tolerance. [2011]

A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. [2011]

Effects of pioglitazone and metformin fixed-dose combination therapy on cardiovascular risk markers of inflammation and lipid profile compared with pioglitazone and metformin monotherapy in patients with type 2 diabetes. [2010.12]

Cellular and molecular changes associated with inhibitory effect of pioglitazone on neointimal growth in patients with type 2 diabetes after zotarolimus-eluting stent implantation. [2010.12]

Hydrochloride pioglitazone decreases urinary cytokines excretion in type 2 diabetes. [2010.12]

Efficacy and safety of generic and original pioglitazone in type 2 diabetes mellitus: a multicenter, a double-blinded, randomized-controlled study. [2010.11]

Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers. [2010.10]

Original article. Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin. [2010.10]

Lack of effects of pioglitazone on cardiac function in patients with type 2 diabetes and evidence of left ventricular diastolic dysfunction: a tissue doppler imaging study. [2010.09.23]

A Randomized Pilot Clinical Trial of the Safety of Pioglitazone in Treatment of Patients With Alzheimer Disease. [2010.09.13]

Pioglitazone versus glimepiride on coronary artery calcium progression in patients with type 2 diabetes mellitus: a secondary end point of the CHICAGO study. [2010.09]

Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20). [2010.09]

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. [2010.08.07]

Effects of the peroxisome proliferator-activated receptor (PPAR)-gamma agonist pioglitazone on renal and hormonal responses to salt in diabetic and hypertensive individuals. [2010.08]

Pioglitazone in addition to metformin improves erythrocyte deformability in patients with Type 2 diabetes mellitus. [2010.07.09]

Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis. [2010.07]

Matrix metalloproteinase-9 is increased in obese subjects and decreases in response to pioglitazone. [2010.06]

A 26-week, placebo- and pioglitazone-controlled, dose-ranging study of rivoglitazone, a novel thiazolidinedione for the treatment of type 2 diabetes. [2010.06]

Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. [2010.06]

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. [2010.05.06]

Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19). [2010.05]

Effect of the bile acid sequestrant colesevelam on the pharmacokinetics of pioglitazone, repaglinide, estrogen estradiol, norethindrone, levothyroxine, and glyburide. [2010.05]

Effect of pioglitazone on energy intake and ghrelin in diabetic patients. [2010.04]

Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. [2010.03]

Effects of pioglitazone on subclinical atherosclerosis and insulin resistance in nondiabetic renal allograft recipients. [2010.03]

Pioglitazone compared with metformin increases pericardial fat volume in patients with type 2 diabetes mellitus. [2010.01]

Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients. [2010.01]

Effect of pioglitazone on various parameters of insulin resistance including lipoprotein subclass according to particle size by a gel-permeation high-performance liquid chromatography in newly diagnosed patients with type 2 diabetes. [2010]

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. [2010]

Effects of the peroxisome proliferator-activated receptor (PPAR)-gamma agonist pioglitazone on renal and hormonal responses to salt in diabetic and hypertensive individuals. [2010]

[Evidences demonstrating the effects of anti-atherosclerotic actions of pioglitazone--special emphasis on PROactive Study and PERISCOPE Study]. [Article in Japanese] [2010]

Long-term glycaemic effects of pioglitazone compared with placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18). [2009.12]

Modulation of adipokines and vascular remodelling markers during OGTT with acarbose or pioglitazone treatment. [2009.12]

Long-term effects of pioglitazone in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity. [2009.12]

Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM. [2009.12]

Pioglitazone improves insulin resistance and decreases blood pressure in adult patients with congenital adrenal hyperplasia. [2009.12]

CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone. [2009.12]

Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. [2009.11.16]

Comparative study of low-dose pioglitazone or metformin treatment in Japanese diabetic patients with metabolic syndrome. [2009.11]

Pioglitazone treatment enlarges subcutaneous adipocytes in insulin-resistant patients. [2009.11]

Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM. [2009.10.14]

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. [2009.10]

Addition of mitiglinide to pioglitazone monotherapy improves overall glycemic control in Japanese patients with type 2 diabetes: a randomized double blind trial. [2009.10]

Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17). [2009.10]

Effects of bed-time insulin versus pioglitazone on abdominal fat accumulation, inflammation and gene expression in adipose tissue in patients with type 2 diabetes. [2009.10]

Pioglitazone improves insulin resistance and decreases blood pressure in adult patients with congenital adrenal hyperplasia. [2009.09.15]

CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone. [2009.09.10]

Low-dose pioglitazone and low-dose flutamide added to metformin and oestro-progestagens for hyperinsulinaemic women with androgen excess: add-on benefits disclosed by a randomized double-placebo study over 24 months. [2009.09]

Actos Now for the prevention of diabetes (ACT NOW) study. [2009.07.29]

Long-term lipid effects of pioglitazone by baseline anti-hyperglycemia medication therapy and statin use from the PROactive experience (PROactive 14). [2009.07.15]

Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients. [2009.07]

Efficacy and safety of pioglitazone in patients with ST elevation myocardial infarction treated with primary stent implantation. [2009.07]

Pioglitazone vs glimepiride: Differential effects on vascular endothelial function in patients with type 2 diabetes. [2009.07]

A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis. [2009.06.25]

A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study). [2009.06]

Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. [2009.06]

Impact of insulin sensitivity treatment with pioglitazone on endothelial function in non-diabetic patients with arterial hypertension. [2009.05]

Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with type 2 diabetes: a double-blind, placebo-controlled, clinical trial. [2009.05]

Prevention of weight gain in adult patients with type 2 diabetes treated with pioglitazone. [2009.05]

Effects of rosiglitazone and pioglitazone on lipoprotein metabolism in patients with Type 2 diabetes and normal lipids. [2009.05]

Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. [2009.04.21]

Efficacy and safety of combination Acitretin and Pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: a randomized, double-blind, placebo-controlled clinical trial. [2009.04]

Free fatty acid kinetics during long-term treatment with pioglitazone added to sulfonylurea or metformin in Type 2 diabetes. [2009.04]

Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial. [2009.04]

Retinol-binding protein 4 in polycystic ovary syndrome--association with steroid hormones and response to pioglitazone treatment. [2009.04]

Rapid improvement of carotid plaque echogenicity within 1 month of pioglitazone treatment in patients with acute coronary syndrome. [2009.04]

Effects of pioglitazone on ovarian stromal blood flow, ovarian stimulation, and in vitro fertilization outcome in patients with polycystic ovary syndrome. [2009.03.24]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017